Trials / Terminated
TerminatedNCT03400176
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Patients enrolled to the study had chronic lymphocytic leukemia (CLL) and received ibrutinib. Patients had either received ibrutinib for one year without having had a complete response or patients developed a resistance mutation to ibrutinib. This study had two parts, a dose escalation part and a dose expansion part.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VAY736 | Experimental |
| DRUG | ibrutinib | Approved medication |
Timeline
- Start date
- 2018-04-09
- Primary completion
- 2023-09-29
- Completion
- 2023-09-29
- First posted
- 2018-01-17
- Last updated
- 2025-05-16
- Results posted
- 2025-05-13
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03400176. Inclusion in this directory is not an endorsement.